Eton Pharmaceuticals
Yahoo Finance • 23 days ago
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today an... Full story
Yahoo Finance • last month
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growthClo... Full story
Yahoo Finance • last month
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
- Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study - - Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmace... Full story
Yahoo Finance • 2 months ago
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today a... Full story
Yahoo Finance • 2 months ago
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients – – $0 co-pay for all eligible patients and best-in-class patient support services – – Now available exclusively through Optime... Full story
Yahoo Finance • 2 months ago
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the product’s approval – DEER PARK, Ill., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals,... Full story
Yahoo Finance • 3 months ago
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ann... Full story
Yahoo Finance • last year
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growthGenerated $0.9 million in positive cash flow from operations; ended qu... Full story
Yahoo Finance • last year
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients sufferin... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
-- Expect Q1 2024 product launch -- -- Nitisinone market estimated to be more than $50 million annually -- -- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharma... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelse... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the U.S. Food... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
Q4 2022 revenue of $8.5 millionQ4 Product sales and royalty revenue up 220% from prior year and 9% from Q3Q4 positive net incomeManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Et... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
-- Product is targeting rare pediatric endocrinology condition -- -- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innov... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will repo... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022 Strong sales growth of ALKINDI SPRINKLE® and Carglumic AcidThird commercial product, Betaine Anhydrous, added to rare disease p... Full story
Yahoo Finance • 2 years ago
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will repor... Full story
Yahoo Finance • 3 years ago
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announce... Full story
Yahoo Finance • 3 years ago
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announce... Full story
Yahoo Finance • 3 years ago
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on rare disease strategyU.S. Food and Dru... Full story
